Category Archives: TDF2

  1. Differing Truvada Drug Levels in Vaginal and Rectal Tissue Offer Clues to HIV PrEP Puzzle

    via HIVandHepatitis.com, by Liz Highleyman The 2 drugs in the Truvada pill — tenofovir and emtricitabine — reach different concentrations in human cervical, vaginal, and rectal mucosa tissues and fluids, according to new research published in the December 7, 2011, issue of Science Translational Medicine. Lower drug levels in the female genital tract suggest that women may Read More >>

    Africa, FEM-PrEP, iPrEx, Partners PrEP, PrEP, rectal transmission, TDF2, Truvada
  2. Closure of oral Tenofovir arm in VOICE Pre-Exposure Prophylaxis trial: PrEP as a “niche intervention”?

    via Incidence, by Roger J. Tatoud The Microbicides Trial Network (MTN) September 28th that its VOICE (Vaginal and Oral Interventions to Control the Epidemic, MTN003) HIV Pre-Exposure Prophylaxis (PrEP) prevention study will discontinue the daily oral tenofovir arm of the trial. The decision follows an interim review of the trial’s data by its Data Safety and Monitoring Board Read More >>

    FEM-PrEP, Microbicide Trials Network, Microbicides, PrEP, TDF2
  3. Washington D.C.: Public Meeting on Safety Issues in PrEP

    An invitation from the Forum for Collaborative HIV Research: Safety Issues in Pre-exposure Prophylaxis for HIV negative individuals, proposals for management of safety concerns, and pending plans for scale-up Forum for Collaborative HIV Research 1608 Rhode Island Avenue, NW Washington, DC 20036 August 19, 2011 8:30am – 4:00pm The Forum for Collaborative HIV Research has been tasked Read More >>

    Forum for Collaborative HIV Research, HIV/AIDS, iPrEx, new prevention technologies, Partners PrEP, pre-exposure prophylaxis, PrEP, prevention, safety, study, TDF2
  4. Open-Label Extension of iPrEX HIV PrEP Study Begins at 11 Sites in 6 Countries

    Via iPrEX News. The iPrEx Open-Label Extension Study (iPrEx OLE), the next phase of the first human study to report efficacy results on pre-exposure prophylaxis (PrEP) to prevent HIV infection, has begun at clinical trial sites around the world. Approximately 2,000 men and transgender women who have sex with men are expected to participate in the 72-week Read More >>

    Africa, FEM-PrEP, HIV, iPrEx, iPrEx OLE, new prevention technologies, Partners PrEP, prevention, TDF2, Treatment